What Has Been the Progress and Growth of the Neoantigen Targeted Therapies Market in Recent Years?
The neoantigen targeted therapies market has seen considerable growth due to a variety of factors.
•The market for neoantigen targeted therapies has experienced rapid expansion in the past few years. It is projected to escalate from $3.4 billion in 2024 to $4.72 billion in 2025, with a compound annual growth rate (CAGR) of 38.7%.
The growth experienced during the historical period is due to improvements in genomic sequencing, the progression of immunotherapy, enhanced comprehension of tumor immunology, successful clinical implementation of checkpoint inhibitors, and advancements in molecular profiling.
What Can Be Expected from the Neoantigen Targeted Therapies Market in the Coming Years?
The neoantigen targeted therapies market is expected to maintain its strong growth trajectory in upcoming years.
• The market for neoantigen targeted therapies is predicted to witness exponential expansion in the coming years. The market value is set to hit $16.01 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 35.7%.
Factors contributing to this anticipated surge during the projection period include advancements in bioinformatics, the growth of precision medicine, development of neoantigen vaccines, strategies for therapeutic combinations, and biomarker validation. Key trends to watch out for during this era include the management of neoantigen resistance, the use of neoantigen-primed adoptive cell therapies, neoantigen-focused combinatorial therapies, the incorporation of real-world data, and improved predictive models.
What Are The Leading Drivers Of Growth In The Neoantigen Targeted Therapies Market?
The surge in cancer occurrences is forecasted to boost the expansion of the neoantigen targeted therapies market. Cancer incidence pertains to the quantity of new instances of cancer within a particular population over a specified duration. Neoantigen-based treatments are often paired to combat various forms of cancer. For example, according to the American Cancer Society (ACS), a volunteer health organization in the US, there were about 1.9 million fresh instances of cancer in 2022 in the United States, this number is considerably larger than the analogue from the earlier years. Also, approximately 609,360 fatalities in the US in 2022 were ascribed to cancer, highlighting the harsh severity and effect this disease has on patients and their kin. Consequently, this escalation in cancer occurrences is propelling the neoantigen targeted therapies market's expansion.
How Are The Segments Defined Within The Global Neoantigen Targeted Therapies Market?
The neoantigen targeted therapies market covered in this report is segmented –
1) By Type: Monotherapy, Combination Therapy
2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies
3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer
4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous
5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications
Subsegments:
1) By Monotherapy: Individual Neoantigen-Targeted Treatments
2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies, Neoantigen-Targeted Therapies Combined With Chemotherapy, Neoantigen-Targeted Therapies Combined With Targeted Therapies
Pre-Book The Neoantigen Targeted Therapies Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The Neoantigen Targeted Therapies Market?
Key players in the neoantigen targeted therapies market are moving towards strategic collaborations to customize cancer treatments, as a way to tackle obstacles of current immunotherapy in managing solid tumors. Strategic collaborations involve businesses utilizing each other's strong points and assets for mutual advantage and success. For example, in January 2023, the bio-technology firm, BioNTech SE from Germany joined forces with the UK Government, a UK-based entity to progress personalized mRNA cancer immunotherapies. The partnership aims to provide tailored treatments for up to 10,000 patients by 2030, with emphasis on several key areas such as the development of cancer immunotherapies, research into infectious disease vaccines, and the establishment of a research and development center in Cambridge. This venture will make the most of the UK's clinical trial network and health data resources to enhance patient recruitment and select trial locations for BioNTech's mRNA treatments. The German company aims to begin its first clinical trials in the UK later this year, these trials would concentrate on cancer vaccines that could eventually be incorporated into regular treatment procedures if proven successful.
Who Are the Key Players in the Neoantigen Targeted Therapies Market?
Major companies operating in the neoantigen targeted therapies market include:
• F. Hoffmann-La Roche AG
• Merck and Co. Inc.
• Bristol Myers Squibb Company
• Eli Lilly and Company
• Kite Pharma Inc.
• Gilead Sciences Inc.
• Amgen Inc.
• Moderna Inc.
• BioNTech SE
• Bavarian Nordic Inc.
• Advaxis Inc.
• Immatics NV
• Precision Biologics Inc.
• Iovance Biotherapeutics Inc.
• Agenus Inc.
• Achilles Therapeutics Plc
• Medigene AG
• Gritstone Bio Inc.
• SQZ Biotechnologies Company
• Aduro BioTech Inc.
• Inovio Pharmaceuticals Inc.
• Gradalis Inc.
• EpiVax Inc.
• ISA Pharmaceuticals BV
• Vaxon Biotech SA
• Ziopharm Oncology
• Genocea Biosciences Inc.
• Cellular Biomedicine Group Inc.
• Immunovaccine Inc.
What Is The Most Dominant Region In The Neoantigen Targeted Therapies Market?
North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
